Phase 3 Results - HEMLIBRA

Phase three results of the Emicizumab (HEMLIBRA) study has been proven safe and effective for Hemophilia A patients with factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH).

What is HEMLIBRA?

HEMLIBRA, (Emicizumab), is a medication that restores the function of missing activated factor VIII in Hemophilia A patients. Emicizumab is a subcutaneous shot that has been developed by Chugai Pharmaceutical Co., Ltd. It is also being co-developed globally by Roche, Chugai, and Genentech and has been approved in multiple countries including the United States and Japan.

More about HEMLIBRA: https://www.hemlibra.com/patient.html

The Study:

For up to two years, patients have taken emicizumab subcutaneously once a week. 82.6% of the patients had no treated bleeds, meaning the mean annualized bleed rate for treated bleeds was 0.5.